SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy Co. is currently trending as a high-volatility trading vehicle following its recent merger and debut on the NASDAQ, fueling intense debate between bulls citing massive Arctic oil exploration potential and bears labeling it a speculative project. The community is deeply divided, with active discussions focused on the company's drilling partnerships, the strategic value of its Jameson Land Basin licenses, and aggressive short-selling dynamics.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The Sperm Whale is drawing significant attention as a speculative meme token, with the community actively debating whether it is a legitimate high-growth opportunity or a coordinated pump-and-dump scheme. Traders are closely monitoring volatility and potential chart patterns while encouraging others to buy the dips to fuel further momentum.

Solphin

Solphin is gaining traction as community members aggressively promote the token on social platforms, drawing comparisons to other high-volatility meme coins within the Solana ecosystem. Investors are actively discussing early-entry opportunities and potential collaborations with other established projects to drive hype.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending as investors debate the impact of escalating geopolitical tensions in the Middle East and concerns over persistent inflation on broader equity markets. Community discussion is sharply divided between long-term holders advocating for consistent dollar-cost averaging through the volatility and short-term traders concerned about potential market corrections and a prolonged economic downturn.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Orcasm is trending as part of a broader investor rotation into ocean-themed meme coins, with community members actively discussing its potential for high growth following similar market movements. While some participants are aggressively promoting the coin's low market cap and potential for rapid gains, others remain skeptical of its long-term viability and the sustainability of this current trend.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is seeing renewed community interest driven by its role in powering on-chain economies and gaming ecosystems, with investors viewing current price action as a potential accumulation zone for a long-term rebound. Traders are actively discussing the token's recovery potential alongside the broader altcoin market, often citing anticipation for gaming-related catalysts and technical setups as key indicators for a possible rally.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is generating significant buzz among retail traders who are actively comparing it to other high-volatility meme coins and coordinating buying efforts to trigger upward momentum. The community is heavily focused on low market cap entry points, debating potential price catalysts, and sharing profit-taking strategies while navigating the speculative nature of these high-risk assets.

Spring Valley Acquisition Corp. III is a blank check company. It was created for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on March 12, 2025 an is headquartered in Dallas, TX.

Spring Valley Acquisition Corp III - Ordinary Shares - Class A

Spring Valley Acquisition Corp. III is generating significant interest following the announcement of a business combination with General Fusion, aiming to become the first publicly traded pure-play fusion energy company. Investors are closely monitoring the firm's progress toward technical milestones like the Lawson criterion while drawing parallels to other notable energy-sector SPAC deals backed by high-profile figures.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is currently seeing significant investor interest driven by a strategic pivot toward aggressive shareholder returns, including a new five-billion-dollar buyback program and the company's first-ever dividend policy. While the community remains divided between long-term bulls betting on its AI cloud dominance and autonomous ride-hailing expansion versus skeptics wary of geopolitical risks and legacy ad revenue declines, active trading is surging following these capital allocation moves.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as technical indicators like the RSI hit multi-year lows, driven by investor anxiety over heavy AI capital expenditures and broader market volatility. While the community remains divided between those panic-selling and others viewing this as a long-term 'buy-the-dip' opportunity, the stock is currently struggling to find stable support amid deep skepticism regarding the immediate profitability of its AI strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up

Today's top stocks include $LNAI, $HCTI, $TGNT, $KOD, $NAVN, $BTBD

Lunai Bioworks Unveils AI-Driven National Consortium to Fast-Track Chemical Defense Countermeasures

Lunai Bioworks (NASDAQ:LNAI) launched a new national consortium aimed at transforming how the United States develops medical countermeasures against emerging chemical threats. Operating through its subsidiary BioSymetrics, the company introduced the Pathfinder Consortium, an academic-industry alliance designed to unify historically fragmented chemical defense efforts across government, academia, and biotech into a single, execution-focused platform.

<ul class="summary-bullets"><li>The deal would expand Lunai’s capacity to develop treatments for neurological disorders.</li><li>The transaction is executed through Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share.</li><li>The acquired technology enables compounds to remain inactive in the body until they reach the brain, where they are selectively activated.</li></ul>Lunai Bioworks, Inc. (LNAI) announced a $20 million acquisition to advance its central nervous system (CNS) drug development.&nbsp;The company will acquire blood-brain barrier (BBB) delivery technology and Alzheimer's therapeutic assets for $20 million from the Clemann Group, SAS, or its assignee, marking an expansion of Lunai’s capabilities in neurological drug research.<h2 class="st-heading-2">Transforming CNS Drug Delivery</h2>The transaction is structured as Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share, with a cap on beneficial ownership at 19.9% to remain compliant with Nasdaq regulations.&nbsp;The newly acquired delivery platform addresses one of the most persistent challenges in central nervous system (CNS) drug development, which is the effective transport of therapeutics across the blood-brain barrier.The technology ensures that compounds remain inactive in the body until reaching the brain, where they activate to target specific neurological pathways.&nbsp;<a href="https://stocktwits.com/symbol/LNAI">Lunai Bioworks stock</a> traded over 25% higher on Thursday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Strengthening Lunai’s Alzheimer’s Pipeline</h2>This acquisition directly strengthens Lunai’s Alzheimer’s program by combining validated target identification with a strong delivery method. The platform enables advanced treatments for CNS disorders where conventional drugs face penetration limitations, potentially improving both safety and effectiveness.&nbsp;<blockquote>&nbsp;"We are now combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain.”— David Weinstein, CEO, Lunai Bioworks</blockquote>On March 19, Lunai launched the Pathfinder Consortium, a national academic-industry alliance to accelerate the development of chemical countermeasures for battlefield and terrorism threats.&nbsp;LNAI stock has declined by over 35% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-aiff-stock-surge-pre-market-today/cZ3rwPpRIjD">Why Did AIFF Stock Surge Over 20% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen

Why Did LNAI Stock Surge Over 25% Today? 

Lunai is acquiring $20 million in blood-brain barrier delivery tech and Alzheimer’s assets from Clemann Group.

Equity

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS...

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Lunai Bioworks (NASDAQ: LNAI...

Best Manufacturing Stocks To Watch Today - March 17th

Taiwan Semiconductor Manufacturing, Applied Materials, and Lunai Bioworks are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...

<ul class="summary-bullets"><li>In January, Lunai announced a new product named Sentinel, an AI safeguard that is designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents.</li><li>The company said in February that its newly issued patent covers a key first step in its platform that standardizes data and removes bias before AI modeling begins.</li><li>Lunai announced in March that it had furloughed some employees in the U.S. and Canada on February 27, noting that this was a temporary measure.</li></ul>Lunai Bioworks Inc. (LNAI) shares soared more than 200% in Tuesday’s opening trade before shedding some of the gains to hover about 150% higher to chalk a one-month high.While Lunai has&nbsp;not made&nbsp;any&nbsp;announcements recently nor has it made a fresh filing with the U.S. Securities and Exchange Commission (SEC), the stock could be drawing retail interest amid an increased interest in AI on the sidelines of Nvidia’s GTC event.Lunai announced in February that it has locked down its core AI architecture with the issuance of a fresh patent to enable precision disease subtyping.Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.<h2 class="st-heading-2">What Is The Patent About?</h2>Lunai said its patent covers a key first step in its platform that standardizes data and removes bias before AI modeling begins.Since AI drug discovery depends on data quality, the system is designed to detect and fix inconsistencies across genomic, clinical, imaging, and other datasets to improve reliability, the company said.By strengthening this core data layer, Lunai stated that it aims to better identify patient subtypes and link them to the gene networks driving specific diseases.“This patent protects the critical first step in our closed-loop AI architecture, increasing confidence in biomarker discovery, disease stratification, and gene network mapping across our CNS and biodefense programs,” said Lunai CEO David Weinstein.<h2 class="st-heading-2">Lunai Announces Sentinel</h2>In January, Lunai announced a new product named Sentinel, an AI safeguard that is designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents.The company said that Sentinel is a real-time biosecurity layer that screens molecular outputs before they are produced, stopping potentially hazardous designs at the source.<h2 class="st-heading-2">Lunai Announces Furloughs</h2>Lunai announced in March that it had furloughed some employees in the U.S. and Canada on February 27, noting that this was a temporary measure.The company also said that its CEO and CFO have agreed to temporarily defer the payment of their salaries during this period. It noted that this measure will be in place until it is able to secure additional capital.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/LNAI">Lunai Bioworks</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.Meanwhile, Koyfin data shows that the short interest in Lunai Bioworks is at 3.3%, up from 1.5% last week.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260317_101902624_png_c94660d562.webp" alt="LNAI stock short interest as on March 17, 2026" width="2400" height="1240"><figcaption>LNAI stock short interest as on March 17, 2026 | Koyfin</figcaption></figure>The company announced in February that it had received a delisting notice from the Nasdaq, while adding that the exchange had granted a request for a hearing, which has been scheduled for March 26, 2026. As a result, the delisting action has been stayed pending a final decision by the exchange.<a href="https://stocktwits.com/symbol/LNAI">LNAI stock</a> is down 42% year-to-date and 93% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF Shares (VTI) and the Vanguard Extended Market Index Fund ETF Shares (VXF) are up 18% in this period.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-nvidia-partnership-quells-wall-street-concerns-for-ride-hailing-giant/cZ3EJfXRIX0">Uber's Nvidia Partnership For Autonomous Vehicles Quells Wall Street's Concerns For Ride-Hailing Giant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is This Micro-Cap Biotech Stock Up 150% Today?

Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.

Why Is LNAI Stock Skyrocketing Today?

Top Biotech Stocks To Follow Today - March 17th

Vertex Pharmaceuticals, bioAffinity Technologies, Lunai Bioworks, Danaher, Moderna, ImmunityBio, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...

Small Caps Surge on Breakouts, Biotech Validation, and “Real-World” Tech Adoption

Momentum is building across small-cap names this week, with a mix of technical breakouts, clinical validation, and commercialization milestones driving a more constructive tone beneath the surface of the market. $LNAI, $BIAF, $IBRX, $KBLB, $UCAR, $LIDR, $JTAI, $FLYX

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent...

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Lunai Bioworks Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

LNAI
Lunai Bioworks Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LNAI News

LNAILunai Bioworks Inc.